Whitfield B Growdon1, Jolijn Groeneweg2, Virginia Byron2, Celeste DiGloria2, Darrell R Borger3, Rosemary Tambouret4, Rosemary Foster5, Ahmed Chenna6, Jeff Sperinde6, John Winslow6, Bo R Rueda5. 1. Vincent Center for Reproductive Biology, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, United States; Gynecologic Oncology Division, Vincent Department of Obstetrics & Gynecology, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02115, United States. Electronic address: wgrowdon@partners.org. 2. Vincent Center for Reproductive Biology, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, United States. 3. Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA 02115, United States. 4. Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02115, United States. 5. Vincent Center for Reproductive Biology, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, United States; Gynecologic Oncology Division, Vincent Department of Obstetrics & Gynecology, Massachusetts General Hospital, Boston, MA 02114, United States; Harvard Medical School, Boston, MA 02115, United States. 6. Monogram Biosciences, San Francisco, CA 94080, United States.
Abstract
BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab binding site may confer resistance. The objective of this investigation was to characterize the expression of the p95HER2 truncated variant in EnCa. MATERIALS AND METHODS: With institutional approval, 86 high grade EnCa tumors were identified with tumor specimens from surgeries performed between 2000 and 2011. Clinical data were collected and all specimens underwent tumor genotyping, HER2 immunohistochemistry (IHC, HercepTest®), HER2 fluorescent in situ hybridization (FISH), along with total HER2 (H2T) and p95HER2 assessment with VeraTag® testing. Regression models were used to compare a cohort of 86 breast tumors selected for equivalent HER2 protein expression. RESULTS: We identified 44 high grade endometrioid and 42 uterine serous carcinomas (USC). IHC identified high HER2 expression (2+ or 3+) in 59% of the tumors. HER2 gene amplification was observed in 16 tumors (12 USC, 4 endometrioid). Both HER2 gene amplification and protein expression correlated with H2T values. High p95HER2 expression above 2.8RF/mm2 was observed in 53% (n=54) with significant correlation with H2T levels. When matched to a cohort of 107 breast tumors based on HercepTest HER2 expression, high grade EnCa presented with higher p95 levels (p<0.001). CONCLUSIONS: These data demonstrate that compared to BrCa, high grade EnCa expresses higher levels of p95HER2 possibly providing rationale for the trastuzumab resistance observed in EnCa.
BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab binding site may confer resistance. The objective of this investigation was to characterize the expression of the p95HER2 truncated variant in EnCa. MATERIALS AND METHODS: With institutional approval, 86 high grade EnCa tumors were identified with tumor specimens from surgeries performed between 2000 and 2011. Clinical data were collected and all specimens underwent tumor genotyping, HER2 immunohistochemistry (IHC, HercepTest®), HER2 fluorescent in situ hybridization (FISH), along with total HER2 (H2T) and p95HER2 assessment with VeraTag® testing. Regression models were used to compare a cohort of 86 breast tumors selected for equivalent HER2 protein expression. RESULTS: We identified 44 high grade endometrioid and 42 uterine serous carcinomas (USC). IHC identified high HER2 expression (2+ or 3+) in 59% of the tumors. HER2 gene amplification was observed in 16 tumors (12 USC, 4 endometrioid). Both HER2 gene amplification and protein expression correlated with H2T values. High p95HER2 expression above 2.8RF/mm2 was observed in 53% (n=54) with significant correlation with H2T levels. When matched to a cohort of 107 breast tumors based on HercepTest HER2 expression, high grade EnCa presented with higher p95 levels (p<0.001). CONCLUSIONS: These data demonstrate that compared to BrCa, high grade EnCa expresses higher levels of p95HER2 possibly providing rationale for the trastuzumab resistance observed in EnCa.
Authors: Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope S Rugo; George Sledge; Gursel Aktan; Catherine Ellis; Allison Florance; Svetislava Vukelja; Joachim Bischoff; José Baselga; Joyce O'Shaughnessy Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: Jolijn W Groeneweg; Silvia F Hernandez; Virginia F Byron; Celeste M DiGloria; Hector Lopez; Vanessa Scialabba; Minji Kim; Ling Zhang; Darrell R Borger; Rosemary Tambouret; Rosemary Foster; Bo R Rueda; Whitfield B Growdon Journal: Clin Cancer Res Date: 2014-10-07 Impact factor: 12.531
Authors: Jeff Sperinde; Xueguang Jin; Jayee Banerjee; Elicia Penuel; Anasuya Saha; Gundo Diedrich; Weidong Huang; Kim Leitzel; Jodi Weidler; Suhail M Ali; Eva-Maria Fuchs; Christian F Singer; Wolfgang J Köstler; Michael Bates; Gordon Parry; John Winslow; Allan Lipton Journal: Clin Cancer Res Date: 2010-07-27 Impact factor: 12.531
Authors: T A Christianson; J K Doherty; Y J Lin; E E Ramsey; R Holmes; E J Keenan; G M Clinton Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: Gini F Fleming; Michael W Sill; Kathleen M Darcy; D Scott McMeekin; J Tate Thigpen; Lisa M Adler; Jonathan S Berek; Julia A Chapman; Paul A DiSilvestro; Ira R Horowitz; James V Fiorica Journal: Gynecol Oncol Date: 2009-10-18 Impact factor: 5.482
Authors: C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan Journal: Br J Cancer Date: 2006-03-13 Impact factor: 7.640
Authors: Carrie L Robinson; Beth T Harrison; Azra H Ligon; Fei Dong; Valeria Maffeis; Ursula Matulonis; Marisa R Nucci; David L Kolin Journal: Mod Pathol Date: 2020-10-19 Impact factor: 7.842
Authors: Jennifer S Woo; Sophia K Apple; Peggy S Sullivan; Jian-Yu Rao; Nora Ostrzega; Neda A Moatamed Journal: Diagn Pathol Date: 2016-10-22 Impact factor: 2.644
Authors: Helen J MacKay; Douglas A Levine; Victoria L Bae-Jump; Daphne W Bell; Jessica N McAlpine; Alessandro Santin; Gini F Fleming; David G Mutch; Kenneth P Nephew; Nicolas Wentzensen; Paul J Goodfellow; Oliver Dorigo; Hans W Nijman; Russell Broaddus; Elise C Kohn Journal: Oncotarget Date: 2017-08-03
Authors: Mari Kyllesø Halle; Ingvild Løberg Tangen; Hege Fredriksen Berg; Erling Andre Hoivik; Karen K Mauland; Kanthida Kusonmano; Anna Berg; Antoni Hurtado; Karl Henning Kalland; Anne M Øyan; Ingunn Stefansson; Olav K Vintermyr; Henrica M Werner; Ingfrid S Haldorsen; Jone Trovik; Helga B Salvesen; Camilla Krakstad Journal: Br J Cancer Date: 2017-11-23 Impact factor: 7.640
Authors: Daniel E Carvajal-Hausdorf; Kurt A Schalper; Yalai Bai; Jonathan Black; Alessandro D Santin; David L Rimm Journal: Gynecol Oncol Date: 2017-02-11 Impact factor: 5.482
Authors: J Edgardo Hernández; Ailyn González-Montiel; Jesús C Ceb Allos-Villalva; David Cantú; Salim Barquet; Anny Olivares-Mundo; Luis A Herrera; Diddier Prada Journal: J Cancer Res Ther (Manch) Date: 2019-12-03